StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences gross margin

Gross margin is gross profit as a percentage of revenue.

Evofem Biosciences's gross margin for the twelve months ending Jun 30, 2026 was 75.5%. For fiscal 2025 it was 77.1%, against 80.2% the year before. The highest annual figure on record is 80.2% in fiscal 2024.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202577.1%−3.1
FY2024Dec 31, 202480.2%+15.9
FY2023Dec 31, 202364.3%−9.5
FY2022Dec 31, 202273.8%+23.0
FY2021Dec 31, 202150.8%+55.7
FY2020Dec 31, 2020-4.9%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202680.6%−3.8
Q1 FY2026Mar 31, 202654.4%−2.4
Q4 FY2025Dec 31, 202572.9%−5.8
Q3 FY2025Sep 30, 202581.7%+1.1
Q2 FY2025Jun 30, 202584.4%+2.8
Q1 FY2025Mar 31, 202556.8%−24.2
Q4 FY2024Dec 31, 202478.7%+72.0
Q3 FY2024Sep 30, 202480.7%+4.4
Q2 FY2024Jun 30, 202481.5%+193.7
Q1 FY2024Mar 31, 202481.0%+7.4
Q2 FY2023Jun 30, 20236.7%−72.0
Q1 FY2023Mar 31, 202376.3%+1.4
Q4 FY2022Dec 31, 2022-112.2%−163.0
Q3 FY2022Sep 30, 202273.6%+29.4
Q2 FY2022Jun 30, 202278.7%+23.9
Q1 FY2022Mar 31, 202274.9%+20.7
Q4 FY2021Dec 31, 202150.8%+40.7
Q3 FY2021Sep 30, 202144.2%+58.2
Q2 FY2021Jun 30, 202154.8%–
Q1 FY2021Mar 31, 202154.2%–
Q4 FY2020Dec 31, 202010.1%–
Q3 FY2020Sep 30, 2020-14.0%–

More Evofem Biosciences figures

See a number that looks wrong?